12:00 AM
Apr 28, 2008
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 1Q08 EPS est 1Q08 EPS actual Outcome Growth from 1Q07 4/25 cls Wk chg % chg Mcap chg 4/25 Mcap
Actelion (SWX:ATLN) NA CHF0.63 NA -28% CHF53.80 CHF4.3 9% $526.2 $6,584.2
Actelion reported that first quarter revenues rose 11% to CHF321.6M ($319.1M) from CHF290.4M in 1Q07, including CHF287.6M ($285.3M) in sales of Tracleer bosentan for pulmonary arterial hypertension (PAH). The company also disclosed it discontinued development of tezosentan because it concluded the drug "would have required far larger studies than anticipated." The endothelin receptor antagonist was in Phase III testing to treat right ventricular failure (RVF) associated with difficult separation from bypass (DSB) in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) (see B18).
Affymetrix (NASDAQ:AFFX) $0.00 -$0.02 Missed by $0.02 NA $10.68 -$0.48 -4% -$32.9 $731.6
EPS excludes certain charges. Revenues for 1Q08 were $79.6M, excluding a one-time $90M payment from a patent suit settlement. 1Q07 revenues were $80.4M. Shares fell earlier this month when the company cut full-year revenue guidance to $490-$510M from $505-525M.
Amgen (NASDAQ:AMGN) $1.04 $1.12 Beat by $0.08 4% $42.25 -$0.82 -2% -$893.0 $46,010.3
Revenues were $3.61B, down 2% from $3.69B in 1Q07. R&D expenses fell to $661M from $803M in the year ago period. Amgen said the 18% decrease resulted from lower staff-related costs and other expense reductions from its restructuring, cost recoveries from deals with Daiichi Sankyo (Tokyo:4568; Osaka:4568) and Takeda (Tokyo:4502) and lower clinical trial costs. Sales of Aranesp for anemia were down 25%, to $761M from over $1B in 1Q07, largely from changes in labeling and reimbursement for all erythropoiesis-stimulating agents (ESAs). Sales of neutropenia products Neupogen and Neulasta were $1.1B, up 7% from $1B in 1Q07. Sales of Enbrel for rheumatoid arthritis (RA) and other inflammatory indications were up 30% to $951M in North America. The increase includes $120M in wholesaler inventory loading, plus increases in patients and average net sales price. Wyeth (NYSE:WYE)...

Read the full 1800 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >